Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 42Urinary Bladder Neoplasms 18Carcinoma, Non-Small-Cell Lung 18Ovarian Neoplasms 11Triple Negative Breast Neoplasms 10Neoplasm Metastasis 10Nasopharyngeal Carcinoma 10Breast Neoplasms 10Lymphoma, Large B-Cell, Diffuse 9Fallopian Tube Neoplasms 9Lung Neoplasms 8Carcinoma, Transitional Cell 8Biliary Tract Neoplasms 7Recurrence 6Gallbladder Neoplasms 6Neoplasms 5Cholangiocarcinoma 5Non-Muscle Invasive Bladder Neoplasms 4Colorectal Neoplasms 4Urothelial Cancer 3Stomach Neoplasms 3Melanoma 3Lymphoma, Non-Hodgkin 3Lymphoma 3Carcinoma 3Uterine Cervical Neoplasms 2Urethral Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Pancreatic Adenocarcinoma 2Non Small Cell Lung Carcinoma NSCLC 2

Interventions

enzalutamide 1Gemcitabine 1Docetaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Fibromatosis, Gingival, 2 × Gemcitabine × Clear all
NCT05919537 2025-04-18

Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation

Hummingbird Bioscience

Phase 1 Active not recruiting
68 enrolled
GastrointestinalThoracic

Fibromatosis, Gingival, 2, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡